Chad E. Davis, Ph.D.
Partner | Boston
Chad E. Davis, Ph.D.

Chad E. Davis, Ph.D. counsels companies, investors, and entrepreneurs on intellectual property matters, especially patent matters. Dr. Davis has extensive experience in prosecution and strategic development of worldwide patent portfolios, intellectual property due diligence, risk assessment through, for example, validity and infringement analyses, post-grant patent proceedings, and intellectual property contracts.

Dr. Davis represents clients in a diverse range of technologies, including pharmaceuticals, drug delivery technologies, crystal forms, organic dyes, chemical processes, polymers, proteins, antibodies, stem cell technology, medical diagnostics, medical imaging, microfluidic devices, adhesives, analytical chemistry, foams, cosmetics, and optical technologies.  For companies developing pharmaceuticals, Dr. Davis provides counsel through all aspects of the business cycle with particular acumen for developing and implementing strategies to maximize worldwide patent and regulatory exclusivities for the pharmaceutical product.

In 2024 and 2023, Dr. Davis was named a Leading Lawyer by The Legal 500 US for Intellectual Property: Patents: Prosecution, being described as having “a business-centric approach to IP, incorporating business strategy in his recommendations on patent prosecutions”. He was also recognized as a leading Intellectual Property lawyer by The Best Lawyers in America 2025. He is routinely recognized as an IAM Patent 1000 World’s Leading Patent Practitioner in Massachusetts, who in 2024, described him as “another impressive name for patent strategy and due diligence work”, whose “background in chemistry establishes him as a partner to life sciences industry players.” Dr. Davis was also named as a “Rising Star” for Patent Prosecution and Patent Strategy & Management by LMG Life Sciences 2024. In 2023, IAM described Dr. Davis as someone who “thinks holistically on how to protect his clients’ IP” and “has an excellent grasp of the science, but also knows how to use this knowledge to achieve his clients’ business goals.” In 2022, IAM praised him as someone who "works creatively and pragmatically and has exceptional analytical skills, great strategic vision and a gift for communicating complex IP insights so they are easy to understand." In 2021, IAM referred to Dr. Davis as "another go- to in Boston and an essential partner to drug companies throughout all phases of the product development lifecycle." In 2019, Dr. Davis was recognized by The Legal 500 US for Industry focus: Healthcare: Life Sciences. Dr. Davis was also recognized by the National Law Journal as a "Rising Star" in the Boston area.

  • Centrexion Therapeutics Corporation, a pharmaceutical company developing medicines to treat pain, to manage intellectual property matters including development and implementation of strategies to procure patent protection for multiple small molecule therapeutic agents in human clinical trials
  • Lycera Corporation, a pharmaceutical company developing medicines to treat autoimmune disease and cancer, to manage intellectual property matters including development and implementation of strategies to procure patent protection for multiple small molecule therapeutic agents in human clinical trials
  • Rafael Pharmaceuticals, Inc., a pharmaceutical company developing medicines to treat cancer, to manage intellectual property matters including development and implementation of strategies to procure patent protection for small molecule therapeutic agents being developed for treatment of cancer
  • Implements patent portfolio strategies to establish domestic and international patent protection and performs intellectual property due diligence investigations on behalf of investors, financial institutions, and companies in advance of investments in privately held companies and public offerings of securities for public companies
  • Counsels clients on intellectual property risk assessment, post-grant patent proceedings and disputes concerning ownership, inventorship, validity and infringement of intellectual property rights
  • Develops strategies for maximizing worldwide patent and regulatory exclusivities for companies developing pharmaceuticals
  • Counsels clients on intellectual property contract matters

Includes matters handled at Dechert or prior to joining the firm.

  • Managing Intellectual Property Life Sciences Forum 2020 — Virtual (September 24, 2020)
    Speaker, "Due Diligence Case Study" panel. 
  • 3rd Annual Life-Sciences Patent Network Spring Conference — Boston, MA (April 25, 2019)
    Moderator, "IP Portfolio Management: In-house Counsel Day-to-Day Challenges in Prosecuting and Enforcing Patents."
  • US Life Sciences Industry in the 2018 Landscape: Significant Trends and Developments Explored Webcast — The Knowledge Group (September 5, 2018)
Services Industries
    • Ball State University, B.S., 1998, summa cum laude
    • University of Illinois at Urbana-Champaign, Ph.D., Chemistry, 2003
    • Boston College Law School, J.D., 2007
    • Massachusetts
    • United States Patent and Trademark Office
    • American Chemical Society
    • American Intellectual Property Law Association
    • Intellectual Property Owners Association